274 related articles for article (PubMed ID: 19166259)
1. [AIDS and social justice: pharmaceutical industry and economics].
López Guzmán J
Cuad Bioet; 2008; 19(67):563-74. PubMed ID: 19166259
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical industry's corporate social responsibility towards HIV/AIDS.
Khanna AK
J Postgrad Med; 2006; 52(3):194-6. PubMed ID: 16855320
[TBL] [Abstract][Full Text] [Related]
3. Global patent police block cost-reduction efforts.
Kasper T
GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
[TBL] [Abstract][Full Text] [Related]
4. Companies reduce prices for HIV drugs in developing countries.
Gottlieb S
Bull World Health Organ; 2000; 78(6):862. PubMed ID: 10916926
[TBL] [Abstract][Full Text] [Related]
5. AIDS drugs & the pharmaceutical industry: a need for reform.
Griffin MT
Am J Law Med; 1991; 17(4):363-410. PubMed ID: 1812767
[TBL] [Abstract][Full Text] [Related]
6. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
7. Ethics and AIDS drugs.
Dowell W
Time; 1999 Jul; 154(2):49. PubMed ID: 10538646
[No Abstract] [Full Text] [Related]
8. New strategies for innovation in global health: a pharmaceutical industry perspective.
Witty A
Health Aff (Millwood); 2011 Jan; 30(1):118-26. PubMed ID: 21209447
[TBL] [Abstract][Full Text] [Related]
9. Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.
Hale VG; Woo K; Lipton HL
Health Aff (Millwood); 2005; 24(4):1057-63. PubMed ID: 16012146
[TBL] [Abstract][Full Text] [Related]
10. Beyond our borders.
Sacks R
Body Posit; 1999 Mar; 12(3):28-34. PubMed ID: 11366293
[TBL] [Abstract][Full Text] [Related]
11. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
Lichtenberg FR
Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
[TBL] [Abstract][Full Text] [Related]
13. Patents and access to drugs in developing countries: an ethical analysis.
Sterckx S
Dev World Bioeth; 2004 May; 4(1):58-75. PubMed ID: 15086374
[TBL] [Abstract][Full Text] [Related]
14. Who's in the business of saving lives?
Lee Chang P
J Med Philos; 2006 Oct; 31(5):465-82. PubMed ID: 17079208
[TBL] [Abstract][Full Text] [Related]
15. Access to AIDS treatment in developing countries: a global issue of equity and human rights.
Thomas J
AIDS Anal Asia; 1998 Mar; 4(2):2-4. PubMed ID: 11657713
[No Abstract] [Full Text] [Related]
16. Research-tool patents: issues for health in the developing world.
Barton JH
Bull World Health Organ; 2002; 80(2):121-5. PubMed ID: 11953790
[TBL] [Abstract][Full Text] [Related]
17. The fine line between education and marketing.
Proj Inf Perspect; 1999 Sep; (28):1-3. PubMed ID: 11367352
[TBL] [Abstract][Full Text] [Related]
18. Developing drugs for the developing world: an economic, legal, moral, and political dilemma.
Resnik DB
Dev World Bioeth; 2001 May; 1(1):11-32. PubMed ID: 12870505
[TBL] [Abstract][Full Text] [Related]
19. Medical pharmaceuticals and distributive justice.
Boylan M
Camb Q Healthc Ethics; 2008; 17(1):30-44. PubMed ID: 18462543
[No Abstract] [Full Text] [Related]
20. Ethical issues in palliative care: considerations.
Manima A
J Pain Palliat Care Pharmacother; 2003; 17(3-4):141-9; discussion 151-2. PubMed ID: 15022958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
